GlassScriptPhysician profile
Mariana E Oliva
NPI 1124552724
$5,313.46
in general payments reported to CMS, 2019-2025
33 companies · $461 in 2025
The $461 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.18 · 2022: $546 · 2023: $258 · 2024: $4,025 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,085 · Food and Beverage: $1,137 · Travel and Lodging: $523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,084.99 |
| Food and Beverage | $1,136.59 |
| Travel and Lodging | $522.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,539.57 | 2024 | |
| Astellas Pharma US INC | $286.71 | 2023-2025 | Veozah |
| Abbvie INC. | $199.63 | 2022 | |
| Sumitomo Pharma America, INC. | $136.09 | 2023-2025 | Myfembree |
| Gynesonics, INC. | $119.54 | 2022-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Myovant Sciences INC. | $94.65 | 2022 | |
| Hologic Sales and Service, LLC | $87.20 | 2024-2025 | Thinprep 2000 Processor, Aptima, Fluent Fluid Management System |
| Sage Therapeutics, LLC | $86.71 | 2024 | |
| Organon LLC | $79.90 | 2022-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $78.93 | 2022-2025 | |
| Millicent US INC | $69.14 | 2024-2025 | Intrarosa, Femlyv |
| Dilon Technologies, INC. | $49.37 | 2024 | Hemoblast Bellows |
| Ethicon US, LLC | $41.71 | 2025 | Vistaseal |
| Meditrina | $36.62 | 2023-2025 | |
| Coopersurgical, INC. | $35.63 | 2024-2025 | Paragard T 380a, Ally II Ups |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $31.25 | 2022 | |
| Pfizer INC. | $30.29 | 2022-2023 | |
| Monaghan Medical Corporation | $25.08 | 2024 | Aerobika |
| Idorsia Pharmaceuticals US INC | $24.65 | 2023 | Quviviq |
| Boston Scientific Corporation | $23.18 | 2019 | |
| Novo Nordisk INC | $22.75 | 2025 | Wegovy |
| Abbott Laboratories | $21.59 | 2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $20.04 | 2025 | |
| Optumhealth Care Solutions, LLC | $19.72 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Daiichi Sankyo INC. | $18.72 | 2022 | |
| Northgate Technologies, INC. | $18.46 | 2024 | Stimsite |
| Mimedx Group, INC. | $18.17 | 2024 | |
| Ascend Therapeutics US, LLC | $17.78 | 2023 | |
| Exeltis, USA INC. | $17.35 | 2025 | Slynd |
| Exact Sciences Corporation | $16.68 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $16.53 | 2024 | Evenity, Prolia |
| Pacira Pharmaceuticals Incorporated | $15.58 | 2023 | Exparel |
| Channel Medsystems, INC. | $14.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariana Oliva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.